Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. - Wikidata - awgldk - TriplyDB

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

http://www.wikidata.org/entity/Q36754449

about

Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.Anticancer oncolytic activity of respiratory syncytial virus.Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Safety and clinical usage of newcastle disease virus in cancer therapy Oncolysis by paramyxoviruses: preclinical and clinical studies.The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Viruses as anticancer drugs.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Measles virus for cancer therapy.Oncolytic viral therapy of malignant glioma Oncolytic virus therapy for prostate cancer.Modified natural nanoparticles as contrast agents for medical imaging.Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.New perspectives in cancer virotherapy: bringing the immune system into play.Use of attenuated paramyxoviruses for cancer therapy.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Therapeutic potential of oncolytic Newcastle disease virus: a critical review.Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.Viral persistence in colorectal cancer cells infected by Newcastle disease virus.Isolation of more potent oncolytic paramyxovirus by bioselection.Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization.Construction of a minigenome rescue system for Newcastle disease virus strain Italien.Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.Recombinant Newcastle disease virus (rL-RVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress.Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.The virus that came in from the cold.PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

P2860

Q24602706-F661C23D-C98A-43CA-89A0-08A7973C100F Q24627862-2C45C894-B019-439C-80F1-BF442093DCA6 Q24631361-0E2BBDD5-0112-41F0-9D26-B72C6AC8FA85 Q33554262-6073677A-F542-4331-9BA4-03A711F75AE0 Q33619829-C1AFF17E-2C35-4BDE-9208-0E0CDB128A2D Q33652517-487C8A59-6CB4-40D9-9C17-F5BCFB2583BC Q33655291-47B7F13A-C160-437D-8248-B4575E161D11 Q33798447-463A8969-946D-4482-93C6-C792F920D5B7 Q35224606-624F61B9-9140-4E69-8C79-A28FC6CDE64E Q35498222-5C01EA91-976E-4CD0-A1A5-261E3EFCDFAF Q35861933-14C3E1DF-BA5B-4754-8E44-DE385D39DD7D Q36405474-F3154726-03DD-4F65-83CC-4469353CC901 Q36664213-87EE6341-0AD0-4B5A-AF83-258134566605 Q36850878-DFEDDF05-A7F8-44F5-B1E4-321E0B70B825 Q36966726-4CA13BF5-A4D7-4CF3-A326-6C89EC36B12C Q37388577-47D8EEC4-5C24-4AB0-BE6D-F61F1A379252 Q37533665-4FE4F929-5FF1-4757-9A55-B4C22D738CB7 Q37615535-BFFA5035-61D5-4450-8DA7-608483C91DAD Q37629944-B63FBE80-6AA7-4D89-A7FF-DB7812BE1962 Q37709761-09923573-6401-4A02-9FB9-6D1E9A38AF05 Q37773253-AA291DD1-5B41-470B-9593-CF4AA71A1761 Q37810599-E66EFF99-52A2-4021-A301-7D7406F773F0 Q37990940-A87928F4-2C91-4234-9C67-59B8DECBEEF0 Q38194135-AC3D114E-52ED-4846-812A-798C475616C0 Q38218674-245A194D-9EAA-4A74-ADAF-B95ED47AADE2 Q38369289-082B31F0-687A-4B0E-A6C2-DAD477528485 Q38860227-C03ABAF4-77E3-4454-AEAA-61D2CD2724DC Q38924554-7D4369E1-154A-4005-8DF6-DA88CF2665D0 Q38953230-55C99108-EBB2-48B0-9395-7CC08308B740 Q38989363-99CBCA3E-4D5A-44B7-A902-8F8E09CB859E Q39392034-33899179-351A-4B8F-A565-75B6E55FED5C Q39611522-4FFA54A0-25CC-442B-8765-7B316727F5D9 Q39612067-5F9BE3E7-CC98-4F1E-8E9E-E09B748B9EEB Q39683647-11A25199-2855-4174-9E5B-AC9E6EDD8F14 Q39789912-837FE9AA-64F2-4B6D-977B-349E463A313A Q40024329-4720540D-5EE2-46FF-A52A-810EF69E1623 Q40705172-ACC43D72-E3F5-46AB-9791-74030CFCD41D Q41168464-44B4FAA2-5204-470D-A59B-1DE6F8FDA23A Q45356848-46B445C8-C141-46FA-8165-8A71FA1A23AF Q52674215-12D7C5F2-3F06-4B06-B0EA-3D49508ECEAE

P2860

Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.

http://www.wikidata.org/entity/Q36754449

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Phase 1 clinical experience us ...... lytic Newcastle disease virus.

@en

type

label

Phase 1 clinical experience us ...... lytic Newcastle disease virus.

@en

prefLabel

Phase 1 clinical experience us ...... lytic Newcastle disease virus.

@en

P1433

Q36754449-8325D8E4-19CE-471B-8F9E-062240022337

P1476

Q36754449-337C6EE6-5874-4C2D-8EFB-A63C8342109C

P2093

Q36754449-2A23E764-8419-49EB-B5E5-63EA4165D300

Q36754449-375D218F-CFAA-4B80-A775-36A69B937188

Q36754449-6AF70928-30DE-4261-A242-A9FA1090F067

Q36754449-7F325D87-5627-4AD9-819D-060A5EB1541C

Q36754449-C8E83DAB-B45F-48C4-82C1-8411067B2E58

Q36754449-D074C4CC-BCA9-4E30-B2D4-0B868CBBAD4E

Q36754449-DC20AFCA-C727-462C-BB74-DD6044729B9B

P304

Q36754449-AC5B63B6-5AE4-4A11-93E8-AFE8F6CD3581

P31

Q36754449-5A03BC2C-08C5-4143-861A-5982A5BC77B9

P356

Q36754449-4FA33C70-0DF8-417D-B29E-A04F7F1C8A70

P433

Q36754449-43BA1152-CD84-4AED-B347-88BCBDCB291E

P478

Q36754449-33BD7A8E-59B8-4FEC-A985-CC87FF865BB3

P577

Q36754449-BE8CAE14-5BEA-448A-BB34-520C24D9892C

P698

Q36754449-1F806C0A-71B7-412C-93CA-0F85B47796F8

P921

Q36754449-EBC6D9DF-2133-4182-967B-377C7E2FE228

P356

156800907780058853

P1433

Current Cancer Drug Targets

P1476

Phase 1 clinical experience us ...... lytic Newcastle disease virus.

@en

P2093

James D O'Neil

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Miller

http://www.w3.org/2001/XMLSchema#string

M Scot Roberts

http://www.w3.org/2001/XMLSchema#string

Michael K Bamat

http://www.w3.org/2001/XMLSchema#string

Robert M Lorence

http://www.w3.org/2001/XMLSchema#string

Stephen N Mueller

http://www.w3.org/2001/XMLSchema#string

William S Groene

http://www.w3.org/2001/XMLSchema#string

P304

157-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/156800907780058853

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17346107

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus